Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial
Christina U. Lorentz, Norah G. Verbout, Michael Wallisch, Matthew W. Hagen, Joseph J. Shatzel, Sven R. Olson, Cristina Puy, Monica Hinds, Owen McCarty, David Gailani, Andras Gruber, Erik Tucker
Dive into the research topics of 'Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial'. Together they form a unique fingerprint.